Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS RATING: 5.23 | Free Publication Certificate
NAAS Rating: 5.23 new

Vol. 6, Issue 2 (2017)

The main aspects of treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia

Sergiy Fedorov
Arrhythmogenic right ventricular dysplasia is a cause of sudden death in young people and athletes. The purpose of this study was to review of modern aspects of management of arrhythmogenic right ventricular dysplasia. Pharmacological options in ARVD treatment consist of antiarrhythmic agents, beta-blockers, and heart failure drug therapy. Implantable defibrillator therapy is the most logical therapeutic strategy for patients with ARVC/D, because the natural history is primarily characterized by the risk of SCD and, only secondarily, by contractile dysfunction leading to progressive heart failure.
Pages: 169-171  |  1102 Views  23 Downloads

The Pharma Innovation Journal
How to cite this article:
Sergiy Fedorov. The main aspects of treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Pharma Innovation 2017;6(2):169-171.
Important Publications Links
The Pharma Innovation Journal

The Pharma Innovation Journal

Call for book chapter
The Pharma Innovation Journal